Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Migraine
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Both males and females
Description
This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements: Provocation Pha...
This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements: Provocation Phase (1 experimental day with intravenous infusion of calcitonin gene-related peptide) Screening/Baseline Phase (4 weeks) Open-Label Treatment Phase (24 weeks)
Tracking Information
- NCT #
- NCT04592952
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Messoud Ashina, MD Danish Headache Center
Get Well Soon